Superworth

Lantheus LNTH

Medical - Diagnostics & Research, Healthcare
$100.31
−0.15%
Market cap
$6.5B
PE
24.3×
10y median 24.0×
Forward PE
n/m
not a meaningful number
Price to sales
4.2×
EV/EBIT
20.8×
Revenue, 12 months
$1.6B
+2% on a year ago
Net margin
17.7%
Free cash flow yield
5.9%

Lantheus trades at 24.3× trailing earnings, near its ten-year median. Revenue was $1.6B over the last twelve months, up 2% on a year earlier with a 18% net margin.

Charts

Financials

Income statement for LNTH, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$319.9M+34%$354M+35%$370M+23%$394.1M+23%$378.7M+18%$391.1M+11%$372.8M+1%$378M−4%$384M+1%$406.8M+4%$377.3M+1%$388.2M+3%
Cost of revenue$120M+31%$124.1M+29%$128.1M−43%$138.3M+16%$136.6M+14%$142.6M+15%$135.1M+5%$137M−1%$161.6M+18%$165.9M+16%$146.4M+8%$146.3M+7%
Gross profit$200M+36%$229.9M+38%$241.8M+214%$255.8M+26%$242.1M+21%$248.5M+8%$237.7M−2%$241M−6%$222.4M−8%$240.9M−3%$230.9M−3%$241.9M+0%
R&D$14.4M+15%$16.8M−94%$48M+57%$60.6M+281%$24.1M+67%$35.3M+110%$36.3M−24%$45.5M−25%$48M+99%$47.5M+34%$39.4M+8%$38.2M−16%
SG&A$73.1M+49%$75.6M+13%$93.4M+67%$92.4M+48%$84.2M+15%$101.5M+34%$99.3M+6%$107.6M+16%$130.7M+55%$116.2M+15%$110.2M+11%$103.4M−4%
$112.4M+31%$137.5M$106.6M$102.7M−17%$133.7M+19%$113.9M−17%$102.1M−4%$88M−14%$43.6M−67%$77.2M−32%$81.3M−20%$100.2M+14%
Interest expense$5.1M+211%$5M+95%$4.9M−3%$4.9M−1%$4.9M−3%$5M+0%$4.8M−1%$4.9M+1%$5M+1%$5.1M+1%$4.9M+1%$4.9M+0%
Pre-tax income$160M+93%$138.4M$171.3M$84.4M−32%$176.1M+10%−$783K$96.5M−44%$104.5M+24%$42.4M−76%$70.4M$156.4M+62%$93.8M−10%
$28M+29%$35M$40.2M$22.3M−25%$45M+61%$11M−69%$23.6M−41%$25.8M+16%$14.6M−68%$16.3M+48%$38M+61%$18.8M−27%
Net income$132M+116%$103.4M$131.1M$62.1M−34%$131.1M−1%−$11.8M$72.9M−44%$78.8M+27%$27.8M−79%$54.1M$118.4M+62%$75M−5%
$1.88+119%$1.47$1.87$0.88−34%$1.79−5%−$0.17$1.02−46%$1.12+27%$0.41−77%$0.81$1.80+77%$1.11−1%
70M−1%70.2M+2%70.1M+4%70.6M−1%73.1M+4%69.2M−1%71.5M+2%70.3M−0%67.7M−7%66.7M−4%65.8M−8%67.5M−4%

Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

R&D: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

SG&A: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Operating income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Income tax: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Net income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them. 21 periods, Q2 FY14 to Q3 FY19: not printed by the filing, worked out from its own lines.

EPS, diluted: 13 periods, Q1 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY14: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY14 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY20 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
LNTHLantheus$6.5B24.3×24.0×n/m4.2×+2%17.7%
BLLNBillionToOne$5.2B170×152×n/m13.1×+90%9.5%
CAICaris Life Sciences$9.1B86.8×78.4×n/m9.2×+85%10.6%
CDNACareDx$4.5B35.9×19.2×n/m9.1×+39%25.9%
BIOBio-Rad Laboratories$9.8B44.4×30.9×n/m3.8×+1%8.6%
VCYTVeracyte$3.9B35.0×66.2×n/m7.0×+17%20.4%
RVTYRevvity$16.9B72.2×35.1×n/m5.8×+4%8.2%
MEDPMedpace$18.1B38.0×34.5×n/m6.5×+25%17.7%
DGXQuest Diagnostics$27.5B24.9×19.3×n/m2.3×+9%9.5%
LHLabcorp$28.9B29.4×19.5×18.8×2.0×+6%7.0%
MTDMettler-Toledo International$34.2B38.4×36.6×34.6×8.3×+7%21.9%
Peer median$13.4B38.2×34.8×26.7×6.8×+13%10.1%

More on Lantheus

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .